Cytotoxic T cells, or CD8+ cytotoxic T cells, as a major component of tumor-infiltrating lymphocytes (TILs), play a central role in antitumor immunity alongside CD4⁺ helper T cells. By isolating and expanding patient-derived TILs and integrating them with cancer organoids, we recreate an immune-active tumor microenvironment to evaluate anticancer agents in a human-relevant context.
Price | 6003€+ |
Organism | Human |
Product Type | Organoid + Cytotoxic T cell |
Tissue | Adaptive |
Disease | – |
Applications
Cancer Organoid
Colorectal Cancer
Non-Small Cell Lung Cancer
Pancreatic Cancer
Breast Cancer
Cholangiocarcinoma
Gastric Cancer
Ovarian Cancer
With the global rise of K-beauty, the cosmetics industry continues to grow steadily. Since the ban on animal testing for cosmetics in Korea in 2017, various alternative testing methods have...
Traditional microscopy methods often require fluorescent labeling to analyze cellular structures, which can be time-consuming and invasive. In contrast, our HT-X1 system allows for high-resolution visualization of cellular morphology without...
Traditional protein analysis has primarily focused on quantifying expression levels within tissue samples. However, recent advances in spatial analysis techniques have shifted attention toward evaluating not only expression levels, but...
We conducted a study focused on identifying disease-related markers using patient-derived tissue samples. However, traditional methods limited our ability to analyze multiple candidate markers simultaneously, and the limited availability of...
Evaluation of the efficacy of an immunotherapeutic agent targeting cytotoxic T cells is possible by co-culturing specific organoids with Primed Cytotoxic T cells, allowing for the selective elimination of particular organoids. This provides a solution for assessing the effectiveness of immunotherapeutic agents targeting cytotoxic T cells in co-culture with cancer organoids.
PD L1 binds to PD 1 and inhibits T cell kiling of tumor cell
Blocking PD L1 or PD 1 allows T cell kiling of tumor cell
The efficacy of atezolizumab was evaluated under co-culture conditions combining tumor organoids with tumor-infiltrating lymphocytes (TILs) or peripheral blood – derived T cells. Higher levels of tumor organoid killing were observed in cultures lacking TILs or T cells, highlighting the influence of immune – tumor interactions on drug response.
The approach of assessing anticancer efficacy within a co-culture of tumor organoids and tumor-infiltrating lymphocytes remains at the research stage globally. Lambda Biologics holds unique patents and offers commercialization-ready platforms for this methodology, advancing the translational study of immunotherapeutic efficacy in a human-relevant tumor microenvironment.
High Responder to control
Low Responder to control
Our advanced platform introduces a new approach to drug development, enabling clinicians and researchers to move beyond the binary classification of responders and non-responders. It allows a detailed examination of patient-specific responses to approved control drugs at varying concentrations. This technology reveals the complex interplay among genetic, regional, and environmental factors and their influence on drug efficacy, providing a pathway to address critical unmet needs before clinical trials.
This example showcases the potential utility of our platform in identifying optimal partners for combination therapy with Immune Checkpoint Inhibitors (ICIs). The research suggests that Combination B could be a more effective strategy in enhancing the efficacy of ICIs. This platform is designed to facilitate such discoveries, offering a clear pathway to improve clinical outcomes through strategic drug pairing.
